Adocia Announces First Half 2021 Financial Results and Provides an Update on Activities - Seite 4

In parallel, a proof-of-concept study in humans has been initiated with BC LisPram. This combination has been specifically designed for Automated Insulin Delivery (pump). This study is being conducted in collaboration with Dr. Ahmad Haidar of McGill University (Canada) and results are expected in the first half of 2022.

• Transforming islet transplantation

In January 2021, Adocia announced the filing of patents on a hydrogel matrix designed to improve Langerhans islets transplantation techniques for cell therapy. The function of this matrix is to maintain the secretory activity of the transplanted cells, while protecting them from the immune system. Adocia's objective is to create an organoid capable of secreting insulin in response to glycemic variations, while avoiding the use of immunosuppressive drugs. An academic collaboration has been established with the Inserm team of Professor Pattou, a world specialist in islets transplantation. Animal trials are underway, prior to human implantation studies.

• Hormone combinations for obesity treatment, a multi-billion euro market undergoing a major transformation

Recently, Adocia initiated new projects in the field of obesity. Patient management is undergoing major transformation, due to the gradual recognition of obesity as a pandemic requiring drug treatment, and to the discovery of the efficacy of certain hormones - which are also involved in diabetes - in weight control. These treatments make it possible to avoid undergoing bariatric surgery.

Adocia has succeeded in combining hormones with synergistic effects and in formulating two hormonal combinations to address the different profiles of obese patients.

These products are intended to be administered by pump so that patients can initiate, with the support of their doctor, a personalized treatment adapted to their lifestyle.

Patents have been filed by Adocia on these hormonal combinations delivered by pump. A proof-of-concept study in humans will be initiated in 2022.

These products could also be developed in other indications such as NASH (Non-Alcoholic Steato-Hepatitis), and type 2 diabetes.

• A stronger Board of Directors

On the governance front, Adocia has strengthened its Board of Directors with the appointment of three new independent members: Dr. Claudia Mitchell, Senior Vice President of Portfolio Strategy at Astellas Pharma; Dr. Katherine Bowdish, President and CEO of PIC Therapeutics; and Stéphane Boissel, CEO of SparingVision.